KBKoenraad De Boulle

Koenraad De Boulle

*This is an algorithmically generated author record based on publicly available information.

Koenraad De Boulle has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patient-Perceived Benefits and Satisfaction of Long-Term Repeated OnabotulinumtoxinA Treatment for Upper Facial Lines: Results From a Global, Multicenter, Retrospective Chart Review and Cross-Sectional Study

    by Koenraad De Boulle, Ada Trindade De Almeida, Sylvia Ramirez, Shannon Humphrey, Amir Moradi, Stefania Roberts, Mansi Mukherjee, Ligia Colucci, Ivan Tan, Nowell Solish, et al.

  • Open Access

    Prevention and Management of Complications With a Hyaluronic Acid–Calcium Hydroxyapatite Hybrid Injectable

    by Wolfgang G Philipp-Dormston, Koenraad De Boulle, David B Eccleston, Rachna Murthy, Karim Sayed, Philippe Snozzi, Fernando Urdiales-Galvez

    Background: A ready-to-use hyaluronic acid–calcium hydroxyapatite (HA-CaHA) hybrid injectable has a dual mode of action for soft-tissue augmentation. Although previous studies have reported a favorable safety profile for HA-CaHA, there is a need for guidelines and recommendations based on real-world clinical experience for the management of complications associated with HA-CaHA. Purpose: This publication provides guidelines and recommendations for the prevention and management of HA-CaHA–related complications. A case study example, treatment algorithms, and injection techniques are included to illustrate the management of complications. Materials and Methods: On January 25, 2023, 13 European physicians were invited to an advisory board meeting to discuss strategies for optimizing patient care, minimizing adverse events (AEs), and identifying data gaps for the prevention and management of complications with HA-CaHA. Results: The management of a subset of AEs, including skin discoloration and edema, was discussed. Small group workshops also shared management algorithms for late noninflammatory adverse reactions, late inflammatory adverse reactions, localized vascular complications, and retinal vascular complications. Best practices for optimal injection techniques were discussed, and injection-technique protocols were developed for treatment sites. Treatment strategies for HA-CaHA–related complications are considered similar to treatment of those resulting from single-agent fillers, and knowledge of anatomy, aseptic technique, correct injection techniques, and appropriate posttreatment care is emphasized. Conclusion: These recommendations on the management of HA-CaHA–related complications may serve as a reference for the broad range of clinicians using HA-CaHA hybrid injectable for different indications and can help optimize patient outcomes and safety.


  • Open Access

    The Patient Journey in Facial Aesthetics: Findings from a European Consensus Meeting on Improving the Quality of Life for Patients Receiving Botulinum Toxin Injections

    by Wolfgang G Philipp-Dormston, Koenraad De Boulle, Yoav Gronovich, Nick Lowe, Karim Sayed, Dimitrios Sykianakis, Serhan Tuncer

    Purpose: Successful treatment of facial lines with botulinum toxin is largely dependent on patient satisfaction; thus, a structured treatment journey that uses patient-reported outcomes (PROs) is helpful for maximizing botulinum toxin results. To develop a patient-centric approach for botulinum toxin injections in facial aesthetics, a group of clinicians met to provide opinions on an optimal treatment journey that uses PROs to quantify treatment benefits on patient quality of life. Patients and Methods: A multidisciplinary panel of 9 clinicians with expertise in facial aesthetic procedures convened for an advisory board that was preceded by and followed up with a structured, multistep consensus discussion. Based on current literature, the panel’s expertise, structured questions, and group discussion, panelists assessed, reconciled, and agreed upon on a patient journey for botulinum toxin treatment in facial aesthetics. Results: Panelists agreed that an optimal patient journey includes screening, assessment, treatment, posttreatment, and follow-up visits. A compact, easy-to-complete, and digital PRO questionnaire should be provided before the visit. During screening, thorough assessments are integral for a successful patient journey because they provide an opportunity to understand treatment goals, address patient concerns, discuss risks and benefits, obtain medication lists/medical history, and take pretreatment photographs. Treatment strategies should include discussing and educating on the approach/choice of botulinum toxin and ensuring patients are comfortable. Posttreatment, clinicians should request intense muscle movements to enhance product uptake and be available to address patient concerns. Finally, during follow-up, PRO questionnaires can be provided to gauge patient satisfaction with treatment, and pretreatment photographs can be provided to allow patients to track their progression. Follow-ups should be scheduled with new patients or those reporting low satisfaction. Conclusion: Establishing a relationship, being aware of the patient’s goals, and developing an individualized care plan allows for a structured, patient-centered treatment journey that promotes positive aesthetic outcomes.


  • Open Access

    Hyaluronic Acid Fillers and ASIA Syndrome: Case Studies [Erratum]

    by Agnieszka Owczarczyk-Saczonek, Koenraad De Boulle

    Erratum for the article Hyaluronic Acid Fillers and ASIA Syndrome: Case Studies


  • Botulinum Toxin in Aesthetic Medicine

    by Barbara Boone, Andreas D. Katsambas, Koen De Boulle

  • Open Access

    Hyaluronic Acid Fillers and ASIA Syndrome: Case Studies

    by Agnieszka Owczarczyk-Saczonek, Koenraad De Boulle

    A continuous increase in the popularity of esthetic procedures with the use of substances as HA has been observed for many years, which might be contributing to an increase in the number of adverse events. The autoimmune/inflammatory syndrome induced by adjuvants (ASIA) can be provoked by hyaluronic acid (HA), which belongs to substances meeting the criteria of adjuvants. Mechanisms of the innate and acquired immune response are activated, leading to the dysregulation of T and B lymphocytes, inability to recognize one’s own antigens, inflammation, damage to one’s own tissues, and ultimately to autoimmunity. The objective of this article is to present a case-series study of patients who developed ASIA syndrome following HA injection after delayed inflammatory reaction (DIR) and emphasize the importance of the need for long-term monitoring after such the reaction. Lack of knowledge about ASIA can lead to delayed diagnosis and serious consequences for the patients. People with a history of immunization reactions, severe allergic reactions, individual predisposition to autoimmunity or family predisposition to autoimmunity and previous exposure to adjuvants require special attention and long-term follow-up. This applies primarily to cases of DIR after the using of bioimplants, especially with treatment resistance, as in our reported cases.


  • Open Access

    High Patient Satisfaction for up to 6 Months With OnabotulinumtoxinA Treatment for Upper Facial Lines

    by Joel L. Cohen, Steven Fagien, Patricia Ogilvie, Koenraad De Boulle, Jean Carruthers, Sue Ellen Cox, Regina Ma Kelly, Julia K. Garcia, Sara Sangha

    BACKGROUND: OnabotulinumtoxinA safety and efficacy are well established for upper facial lines (UFL), including forehead lines (FHL), glabellar lines (GL), and crow's feet lines (CFL). OBJECTIVE: To investigate the association of onabotulinumtoxinA efficacy with patient-reported psychological impacts and satisfaction in UFL. MATERIALS AND METHODS: A pooled analysis of data from 4 pivotal Phase 3 trials (onabotulinumtoxinA vs placebo in FHL ± GL, FHL + GL ± CFL, CFL, and CFL + GL for ≤180 days) evaluated investigator-assessed ≥1-grade severity improvement on the Allergan Facial Wrinkle Scale at Day 30 (responders). Facial Line Outcomes (FLO-11) Questionnaire, Facial Line Satisfaction Questionnaire (FLSQ), and Subject Assessment of Satisfaction of Appearance (SASA) were used to evaluate responder appearance-related psychological impacts and satisfaction. RESULTS: OnabotulinumtoxinA patients, by primary study focus (FHL, GL, or CFL), totaled 921, 921, and 833, respectively; 786 patients received placebo. Most patients were female, White, and aged 45 to 50 years (median). Through 150 days, >42% FHL, >43% GL, and ≥32% CFL patients were onabotulinumtoxinA responders. Responders reported improvements in appearance-related psychological impacts (FLO-11) and high satisfaction (FLSQ and SASA), sustained through ≥150 days. CONCLUSION: A ≥1-grade improvement with onabotulinumtoxinA is a clinically meaningful outcome in UFL, associated with long-lasting improved patient-reported psychological impacts and high satisfaction.


  • Open Access

    The 10-Point Plan 2021: Updated Concepts for Improved Procedural Safety During Facial Filler Treatments [Corrigendum]

    by Izolda Heydenrych, Koenraad De Boulle, Krishan Mohan Kapoor, Dario Bertossi

    Corrigendum for the article The 10-Point Plan 2021: Updated Concepts for Improved Procedural Safety During Facial Filler Treatments


  • Open Access

    The 10-Point Plan 2021: Updated Concepts for Improved Procedural Safety During Facial Filler Treatments

    by Izolda Heydenrych, Koenraad De Boulle, Krishan Mohan Kapoor, Dario Bertossi

    Dermal filler treatments require constant reassessment for improving and safeguarding the rapidly evolving aesthetic field. Suboptimal injection technique, patient selection and product knowledge have touted a concerning increase in filler complications, with new challenges such as the COVID-19 pandemic leading to new paradigms in the understanding, prevention, diagnosis and treatment of complications. The updated 10-point plan has been developed to curtail complications through consideration of causative factors, categorized as patient, product, and procedure-related. Patient-related factors include a preprocedural consultation with careful elucidation of skin conditions (acne, rosacea, dermatitis), systemic disease (allergies, autoimmune disease, underlying bacterial and viral disease (herpes simplex virus, COVID-19 infection), medications (antineoplastic drugs, recreational drugs) and previous cosmetic procedures (including fillers and energy-based devices). Patient assessment should include standardized photography and also evaluate the role of social media, ethnicity, gender, generational, and LGBTQ+ needs. Specified informed consent for both adverse events and their treatment is essential due to the increase in vascular complications, including the risk of blindness. Product-related factors include the powerful advantage of reversibility when using hyaluronic acid (HA) products. Product characteristics such as molecular weight and filler degradation should be understood. Product layering over late or minimally degradable fillers is still inadvisable due to the initial filler being teased into reactivity. Procedural factors such as consistent photographic documentation, procedural planning, aseptic non-touch technique (ANTT), knowledge of topographical anatomy and angiosomes, and technical dexterity including pinch anatomy and needle skills are of pivotal importance. The final section is dedicated to algorithms and checklists for managing and treating complications such as allergic hypersensitivity reactions, vascular events, infection, edema and late-onset adverse events (LOAEs). The updated 10-point plan is a methodical strategy aimed at further minimising the risk of dermal filler complications.